



SDI Review Form 1.6

PART 1:

Journal Name:	<u>International Blood Research & Reviews</u>
Manuscript Number:	2013_IBRR_5340
Title of the Manuscript:	JAK-2V617F Mutation In Acute Leukemia (South Egypt Experience)
Type of the Article	Research Paper

General guideline for Peer Review process is available in this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

- This form has total 7 parts. Kindly note that you should use all the parts of this review form.



SDI Review Form 1.6

PART 2: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments	1. Grammar and spelling should be controlled. 2. The Introduction section should be shortened and thereby the number of references can be reduced. 3. The authors should use the WHO classification when classify their patients. Furthermore, they should divide their manuscript into the four main sections Introduction, Material and methods, Results and Discussion. The present Patients and JAK2 anaysis sections should then constitutie the Material and methods section. 4. The authors should document that their methodology is working by describing patients with detectable JAK2 mutations, e.g. patients with chronic myeloproliferative diseases. 5. The authors should provide more detailed information about their two main patients subsets (acute myeloid and acute lymphoblastic leukemia), including age, gender, race, previous diseases (myelodysplastic syndromes or chronic myeloproliferative neoplasia), previous chemotherapy, membrane molecule expression. 6. The authors should describe the selection/recruitment of patients to their hospital.	1. controlled 2. Shortened 3. We couldn't classify our patients with WHO classification as we don't have facilities or budget to bring all chromosomal Probes, as you know Egypt in the past 2 years faced major political issues which affect our economy consequently this reflected on our institute budget so we used FAB classification 4. We already used positive control from known polycythemia vera positive for JAK-2 V617F 5. Provided 6. 6. Selection and recruitment of patients, all patients in study are newly diagnosed cases either AML or ALL cases usually referred from other hospital after initial diagnosis to our institute as we are the only tertiary and university hospital which treat hematological malignancy in the south of Egypt
<u>Minor</u> REVISION comments	None	



SDI Review Form 1.6

<u>Optional/General</u> comments	This is a small study with a limited scientific interest and confirming previous observations that JAK2 mutations are uncommon in acute leukemias. However, the frequencies of various mutations in AML may vary between different populations, and for this reason the results from a study of a new population has a value.	OK
---	---	----